Regulatory spotlight: Novartis’s remibrutinib likely to progress after positive urticaria trial | #urticaria Pipeline Drugs Market
Мне нравится
Комментарий
Перепост
Regulatory spotlight: Novartis’s remibrutinib likely to progress after positive urticaria trial | #urticaria Pipeline Drugs Market